Multi-scale data reveal a CD24(+) MUCL1(+) tumor subgroup associated with unfavorable prognosis in ER+ breast cancer
This integrative approach, spanning molecular to imaging analyses, provides novel insights into both the biological drivers and clinical implications of MUCL1(+) CD24(+) cells in breast cancer progression.
Authors
- Yao Tian (ORCID: https://orcid.org/0000-0003-4680-6889)
- Linyue Hai (ORCID: https://orcid.org/0000-0002-3082-7741)
- Jing Zeng (ORCID: https://orcid.org/0000-0003-0857-2217)
- Yingxi Li (ORCID: https://orcid.org/0000-0002-3848-1992)
- Dandan Tian (ORCID: https://orcid.org/0000-0002-7540-4072)
- Yue Yu (ORCID: https://orcid.org/0000-0003-2053-9866)
- Zhaohui Chen (ORCID: https://orcid.org/0000-0003-0688-9798)
- Junming Cao (ORCID: https://orcid.org/0009-0004-7581-2959)
Institutions
- Ningbo University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
- Ningbo College of Health Sciences (CN)
- Ningbo University Affiliated Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1695689
- Citations
- 1
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.05